Live Events

CME Requirements By State

Live Events

November
13
Wednesday
7:00 PM

Atopic Dermatitis

A Closer Look at the Atopic Dermatitis Patient Journey: Effective Management Approaches Across the Age and Disease Spectrum

Ruchi S. Gupta, MD, MPH
Northwestern University Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital of Chicago
Center for Food Allergy & Asthma Research (CFAAR)
Chicago, IL

Robert Sidbury, MD, MPH
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

January
27
Mon
2:00 PM
January
28
Tue
4:30 PM
7:00 PM

Eosinophilic Granulomatosis With Polyangiitis

Overcoming Challenges Associated With the Diagnosis and Management of EGPA: An Exploration of Novel Approaches

Praveen Akuthota, MD
University of California San Diego
La Jolla, California

June
10
Wednesday
7:00 PM

Immuno-Oncology

Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team

Brendon Stiles, MD
Associate Professor, Department of Cardiothoracic Surgery
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

June
11
Thursday
08:00 CEST

Leukemia

Transforming Care With BTK Inhibitors in CLL: New Insights on Therapy Selection, Safety, and Sequencing Across the Treatment Continuum

Professor Florence Cymbalista, MD, PhD
Hopital Avicenne, AP-HP
University of Paris 13
Bobigny, France

June
16
Tuesday
18:00 CEST

Leukemia

Transforming Care With BTK Inhibitors in CLL: New Insights on Therapy Selection, Safety, and Sequencing Across the Treatment Continuum

Professor Florence Cymbalista, MD, PhD
Hopital Avicenne, AP-HP
University of Paris 13
Bobigny, France

June
17
Wednesday
7:00 PM

Venous Thromboembolism (VTE)

Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

Alok A. Khorana, MD, FACP, FASCO
Taussig Cancer Institute
Cleveland Clinic Lerner School of Medicine Case Western Reserve University
Cleveland Clinic
Cleveland, Ohio

June
22
Monday
7:00 PM

Gastric Cancer

Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

June
22
Monday
6:30 PM
June
30
Tuesday
12:00 PM

Lymphoma

BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

June
13
Saturday
6:15 PM
June
23
Tuesday
12:00 PM
June
24
Wednesday
7:00 PM
June
25
Thursday
12:00 PM

Endocrinology, Cardiology, and Nephrology

Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases

John B. Buse, MD, PhD
NC Translational and Clinical Sciences Institute
University of North Carolina School of Medicine
Chapel Hill, North Carolina

June
23
Tuesday
7:00 PM

Prostate Cancer

How I Think, How I Treat: Learning to Navigate the Modern Prostate Cancer Landscape

William K. Oh, MD
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York

June
24
Wednesday
7:00 PM

Leukemia

Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

Harry P. Erba, MD, PhD
Duke University Medical Center
Durham, North Carolina

June
25
Thursday
7:00 PM

Lung Cancer

Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

Suresh S. Ramalingam, MD, FACP, FASCO
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

June
29
Monday
7:00 PM

Myelofibrosis

Following the Evidence to Effective Therapy for Myelofibrosis: How Clinicians Can Overcome Challenges in Patient Care in the JAK Inhibitor Era

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

June
30
Tuesday
7:00 PM

Oncology

Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

July
1
Wednesday
7:00 PM

Oncology

How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

July
2
Thursday
11:00 AM

Gastric Cancer

Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances With Novel HER2-Targeted Therapies and Other Agents Into Current Clinical Practice

Josep Tabernero, MD, PhD
Vall d’Hebron University Hospital (HUVH)
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

July
2
Thursday
7:00 PM

Gynecologic Cancers

Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies

Linda R. Duska, MD, MPH
University of Virginia School of Medicine
Charlottesville, Virginia

July
8
Wednesday
7:00 PM
July
9
Thursday
7:00 PM

Bladder Cancer

Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

Arjun Balar, MD
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

July
16
Thursday
7:00 PM

Interstitial Lung Diseases (ILDs)

Differential Diagnosis of Interstitial Lung Diseases: Interpreting HRCT Accurately and Working With a Multidisciplinary Approach

Jonathan H. Chung, MD
The University of Chicago Medicine
Chicago, IL

Steven D. Nathan, MD
Inova Fairfax Hospital
Virginia Commonwealth University-Inova Fairfax Campus
Falls Church, Virginia

July
24
Friday
1:30 PM

Pulmonology

How I Think, How I Treat: Contemporary Insights on Diagnosing and Managing SSc-ILD in an Evolving Treatment Landscape

Lisa H. Lancaster, MD
Vanderbilt University Medical Center
Nashville, Tennessee

August
11
Tuesday
7:00 PM

Lymphoma

Perspectives on Innovative Treatment for B-Cell Malignancies: The Convergence of Precision Medicine With Groundbreaking Therapeutics

John M. Pagel, MD, PhD
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

August
13
Thursday
7:00 PM

Breast Cancer

The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage and Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons

George Plitas, MD
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

August
17
Monday
8:00 PM EDT
September
2
Wednesday
7:00 PM EDT
August
18
Tuesday
8:00 PM EDT
September
1
Tuesday
7:00 PM EDT
August
31
Monday
16:30 CEST
September
15
Tuesday
18:00 CEST

Leukemia

Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction With HSCT

Professor David I. Marks
University Bristol NHS Foundation Trust
Bristol, United Kingdom

September
2
Wednesday
4:45 PM
September
10
Thursday
7:00 PM

Neurofibromatosis

Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

Concetta (Connie) DiDomenico, RN, MSN, PNP-BC, CPHON
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Michael J. Fisher, MD
The Children's Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

September
9
Wednesday
6:00 PM CDT
October
14
Wednesday
4:15 PM CDT
October
20
Tuesday
7:00 PM EDT

Cancer Immunotherapies/Biomarkers

Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine
Yale School of Medicine
Director Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

September
10
Thursday
8:45 AM CDT
October
13
Tuesday
5:45 PM CDT
October
21
Wednesday
7:00 PM EDT

Leukemia

The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Joseph D. Khoury, MD, FCAP
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
11
Friday
6:30 AM

Chronic Lymphocytic Leukemia

Achieving Innovation in CLSeizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential CareL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum

William G. Wierda, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Philip A. Thompson, MB, MS
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
11
Friday
2:30 PM EDT

Multiple sclerosis

What’s New in Relapsing MS? Expert Perspectives on Pathogenesis, Targeting B Cells for Treatment, and Advances in Disease-State Monitoring

Prof. Xavier Montalban
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d’Hebron Barcelona Hospital Campus
Barcelona, Spain

September
11
Friday
5:56 PM

Multiple Myeloma

The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-Based Treatment From CD38 to BCMA

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Robert Z. Orlowski, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
15
Tuesday
7:00 PM

Chronic Kidney Disease

Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse

Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana

September
17
Thursday
9:00 AM

Solid Tumors

The Oncology Nursing Guide to Tumor Treating Fields as a Fourth Modality in Cancer Treatment: Understanding the Science and Evidence and Implementing Critical Nursing Roles in Practice

Suriya Jeyapalan, MD, MPH
Tufts Medical Center
Boston, Massachusetts

Madeline Couch, MSN, FNP-C
Tufts Medical Center
Boston, Massachusetts

September
30
Wednesday
7:00 PM EDT
October
28
Wednesday
7:00 PM China Standard Time (CST)
November
18
Wednesday
7:00 PM AEDT

Tenosynovial Giant Cell Tumors (TGCT)

Solutions for Tenosynovial Giant Cell Tumors: Employing Effective Multimodal and Multidisciplinary Approaches to Patient Care

Robin L. Jones, MD
Royal Marsden Hospital and Institute of Cancer Research
London, England, United Kingdom

October
5
Monday
7:00 PM EDT

Renal Cell Carcinoma

At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

October
12
Monday
7:00 PM EDT

Multiple sclerosis

Realizing the Full Clinical Potential of Sphingosine-1-Phosphate Receptor Modulation to Improve Outcomes in Patients With Multiple Sclerosis

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
International Society for Neuroimmunology
Philadelphia, Pennsylvania

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
15
Thursday
12:00 PM EDT

Multiple sclerosis

What’s New in Relapsing MS? Expert Perspectives on Pathogenesis, Targeting B Cells for Treatment, and Advances in Disease-State Monitoring

Prof. Xavier Montalban
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d’Hebron Barcelona Hospital Campus
Barcelona, Spain

October
18
Sunday
11:15 AM CDT

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Improving Recognition and Management of EGPA: A Multidisciplinary Approach to Individualizing Treatment

Philip Seo, MD, MHS
Johns Hopkins University School of Medicine
The Johns Hopkins Vasculitis Center
Baltimore, Maryland

Michael E. Wechsler, MD
NJH Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

October
19
Monday
7:00 PM EDT
October
28
Wednesday
7:00 PM EDT

SCLC

Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Bhavesh Shah, RPh, BCOP
Boston Medical Center Health System
Boston, Massachusetts

October
20
Tuesday
8:00 AM PDT
October
27
Tuesday
7:00 PM EDT

Neurofibromatosis

Progressive Pathways: Recent Recommendations and Emerging Therapies for Treating NF1 Associated Tumors

Roger J. Packer, MD
Gilbert Family Neurofibromatosis Institute
Brain Tumor Institute
Children’s National Hospital
The George Washington University Medical Center
Washington, DC

October
22
Thursday
9:00 AM EDT
October
28
Wednesday
12:00 PM EDT

Epilepsy

Cannabidiol in the Treatment Arsenal for Severe Epilepsy Syndromes: Practical Guidance for Managed Care Professionals

Orrin Devinsky, MD
NYU Epilepsy Center
NYU Grossman School of Medicine
New York, New York

Sheldon J. Rich, RPh, PhD
SJR Associates, LLC
University of Michigan
Sarasota, Florida

October
23
Friday
9:00 AM EDT

PARP Inhibition

Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks, and Considerations for Decision Making in Managed Care Settings

Kathleen N. Moore, MD, MS
Stephenson Cancer Center
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Kristi Jhangiani, PharmD, BCPS
MedImpact Healthcare Systems
San Diego, California

October
25
Sunday
5:45 PM EDT

Esophageal/GEJ Cancer

Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

Ronan J. Kelly , MD, MBA
Charles A. Sammons Cancer Center at Baylor University Medical Center
Dallas, Texas
Baylor Scott & White Health System (NTx)
Texas A&M University College of Medicine
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins
Baltimore, Maryland
The Translational Genomics Research Institute (TGEN)
Phoenix, Arizona

October
27
Tuesday
5:30 PM EDT
November
10
Tuesday
7:00 PM EST
October
28
Wednesday
8:00 AM CDT
November
4
Wednesday
7:00 PM EST

Emergency Medicine

Emergency Department on Alert: Solving Oncologic Emergency Quandaries During the Immuno-Oncology Era and COVID-19 Pandemic

Jarushka Naidoo, MB, BCH, MHS
Beaumont Hospital
Dublin, Ireland
Johns Hopkins University
Baltimore, Maryland

Andrew Stolbach, MD, MPH
Johns Hopkins Hospital
Johns Hopkins University School of Medicine
Baltimore, Maryland

October
29
Thursday
7:00 PM EDT

Diabetic Macular Edema and Diabetic Retinopathy

Highlighting the Vital Role of Primary Care in Identifying and Optimizing the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

November
5
Thursday
7:00 PM EST

Renal Cell Carcinoma

How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology

David F. McDermott, MD
Beth Israel Deaconess Medical Center
Dana-Farber Harvard Cancer Center Kidney Cancer Program
Harvard Medical School
Boston, Massachusetts

November
7
Saturday
8:00 AM EST

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Improving Recognition and Management of EGPA: A Multidisciplinary Approach to Individualizing Treatment

Eric Gapud, MD, PhD
The Johns Hopkins Vasculitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Michael E. Wechsler, MD
NJH Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

November
8
Sunday
6:00 PM EST
November
17
Tuesday
7:00 PM EST

SSc-ILD

The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management

Flavia Castelino, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Sonye K. Danoff, MD, PhD
Johns Hopkins Medicine
Johns Hopkins Myositis Center
Baltimore, Maryland

November
11
Wednesday
7:00 PM EST

Lung cancer

Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

Suresh S. Ramalingam, MD, FACP, FASCO
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

November
13
Friday
7:00 PM EST
December
1
Tuesday
7:00 PM EST
November
19
Thursday
3:00 PM EST
December
2
Wednesday
7:00 PM EST

Tenosynovial Giant Cell Tumors

The Case for Challenging Conventional Care in Tenosynovial Giant Cell Tumor: Insights on Integrating Targeted Therapy Into Multimodal Management

William D. Tap, MD
Memorial Sloan Kettering Cancer Center
New York, New York

November
20
Friday
3:00 PM EST
December
3
Thursday
7:00 PM EST

GI Stromal Tumor

Personalizing and Prolonging Care in GIST: Expert Guidance on Integrating New TKI Strategies

Margaret von Mehren, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

December
2
Wednesday
1:00 PM EST

Neurofibromatosis Type 1

Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

December
4
Friday
11:00 AM PST
December
15
Tuesday
12:00 PM EST

Non-Hodgkin Lymphoma

Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

Nathan H. Fowler, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

December
4
Friday
8:00 AM PST

Acute Lymphoblastic Leukemia

Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath
University Bristol NHS Foundation Trust
Bristol, United Kingdom

December
4
Friday
7:00 AM PST

Chronic Lymphocytic Leukemia

Mapping the New Era in CLL Management: Precision Medicine, Optimized Therapeutic Sequencing, and Patient Perspectives in Treatment-Naïve and Relapsed Disease

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
4
Friday
7:00 AM PST

Acute Myeloid Leukemia

How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Harry P. Erba, MD, PhD
Duke University Medical Center
Durham, North Carolina

December
4
Friday
7:00 AM PST

Myelodysplastic Syndromes

Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model

Steven D. Gore, MD
National Cancer Institute
Bethesda, Maryland

December
4
Friday
11:00 AM EST
December
17
Thursday
7:00 PM EST

Prostate Cancer

Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes

William K. Oh, MD
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York

December
7
Monday
1:00 PM EST

Chronic Kidney Disease

HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

Steven Fishbane, MD
Northwell Health
Great Neck, New York

Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN
University of Minnesota
Minneapolis, Minnesota

December
8
Tuesday
7:00 PM EST
December
15
Tuesday
7:00 PM EST

Glioblastoma

Rethinking Glioblastoma Care in an Evolving Therapeutic Landscape: Expert Perspectives on Modern Modalities, Novel Agents, and Combinations

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

December
9
Wednesday
12:00 PM EST
December
16
Wednesday
7:00 PM EST

Hematology

Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center
New York, New York

December
12
Saturday
7:00 AM CST

Hyperlipidemia

Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High Risk of ASCVD

Professor Kausik Ray
European Atherosclerosis Society
Imperial Centre for Cardiovascular Disease Prevention
Imperial College London
London, England, United Kingdom

December
15
Tuesday
7:00 PM EST

Ocular Toxicity in Multiple Myeloma

Targeting Ocular Toxicity in Multiple Myeloma: Opportunities for Ophthalmology-Oncology Collaboration

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

December
17
Thursday
7:00 PM EST

Mantle Cell Lymphoma (MCL)

Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

Ian W. Flinn, MD, PhD
Sarah Cannon Research Institute
Nashville, Tennessee

January
12
Tuesday
7:00 PM EST

Multiple Sclerosis

Exploring the Rationale, Results, and Real-World Clinical Potential of BTK Inhibitors in the Management of Multiple Sclerosis

Anne H. Cross, MD
The Manny & Rosalyn Rosenthal - Dr. John L. Trotter MS Center
Washington University School of Medicine
St. Louis, Missouri

Prof. Xavier Montalban
Multiple Sclerosis Centre of Catalonia (Cemcat)
Vall d'Hebron Barcelona Hospital Campus
Barcelona, Spain

January
15
Friday
6:30 PM EST

Immunotherapy for GI Cancers

Checkpoint Inhibition in GI Cancers: Recent Advances in Gastric, Esophageal, and Colorectal Cancers and Their Application in Clinical Practice

Manish A. Shah, MD, FASCO
Weill Cornell Medicine/ NewYork-Presbyterian
New York, New York

January
17
Sunday
7:00 PM EST
January
26
Tuesday
7:00 PM EST

Small Cell Lung Cancer

Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

February
8
Monday
12:30 PM CST
February
23
Tuesday
7:00 PM EST

Acute Myeloid Leukemia (AML)

Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

February
8
Monday
1:30 PM CST
February
25
Thursday
7:00 PM EST

CAR-T Cell Therapy

Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers

Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois

February
9
Tuesday
1:30 PM CST
February
24
Wednesday
7:00 PM EST

Multiple Myeloma

The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT

Robert Z. Orlowski, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Nina Shah, MD
The University of California San Francisco
San Francisco, California

February
10
Wednesday
7:30 AM CST
March
2
Tuesday
7:00 PM EST

Graft-Versus-Host Disease

New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics

Corey Cutler, MD, MPH, FRCP(C)
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Miguel-Angel Perales, MD
Memorial Sloan Kettering Cancer Center
New York, New York

February
10
Wednesday
8:30 AM CST
March
4
Thursday
7:00 PM EST

Myelofibrosis

How to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

Jeanne M. Palmer, MD
Mayo Clinic
Phoenix, Arizona

February
11
Thursday
6:30 PM EST

Prostate Cancer

Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
12
Friday
6:30 PM EST

Bladder Cancer

Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum

Professor Thomas Powles, MBBS, MRCP, MD
Bart’s Cancer Institute
London, United Kingdom

February
13
Saturday
4:30 PM EST

Renal Cell Carcinoma (RCC)

RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

February
18
Thursday
6:10 PM EST

Lung Cancer

New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

Roy S. Herbst, MD, PhD
Yale School of Medicine
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut

Lecia V. Sequist, MD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

February
25
Thursday
2:30 PM CST

Multiple Sclerosis

The Rise of B-Cell Therapies in Relapsing MS: Examining the State of the Science, New Therapeutic Options, and Patient-Centered Clinical Decision-Making

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Ludwig Kappos, MD, FEAN, FAAN
Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
University Hospital Basel and University of Basel
Basel, Switzerland

March
3
Wednesday
7:00 PM EST

Alzheimer’s Disease

Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon

Marwan Sabbagh, MD, FAAN, CCRI
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada

March
15
Monday
7:30 AM PDT

Immuno-Oncology Biomarkers

The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes

Hossein Borghaei, DO, MS
Professor and Chief, Thoracic Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Sanjay Mukhopadhyay, MD
Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland, Ohio

March
16
Tuesday
6:30 AM PDT

HER2/HER3 Testing/Treatment

HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice

Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medical Oncology
Yale School of Medicine
Director Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

Shanu Modi, MD
Section Head, HER2 Breast Program
Associate Professor, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

March
17
Wednesday
7:30 AM PDT
March
24
Wednesday
7:00 PM EDT

NSCLC

Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC

Dara L. Aisner, MD, PhD
Associate Professor
Director, Colorado Molecular Correlates Laboratory
Department of Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

March
19
Friday
3:45 PM EDT

Melanoma

The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy

Jennifer Wargo, MD, MMSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas

March
25
Thursday
4:10 PM EDT
April
8
Thursday
7:00 PM EDT

HCC

At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC

Matthew S. Johnson, MD, FSIR
Indiana University School of Medicine
Indiana University Health
Indianapolis, Indiana

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

April
12
Monday
6:30 PM EDT
April
20
Tuesday
7:00 PM EDT

PARP Inhibition

Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors

Susana Banerjee, MBBS, MA, FRCP, PhD
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, England

April
13
Tuesday
6:30 PM EDT
April
21
Wednesday
7:00 PM EDT

Immuno-Oncology Biomarkers

Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

Suresh S. Ramalingam, MD, FACP, FASCO
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

April
14
Wednesday
12:00 PM CDT
April
26
Monday
12:00 PM CDT
May
7
Friday
12:00 PM CDT
May
12
Wednesday
12:00 PM CDT
May
24
Monday
12:00 PM CDT

Renal Cell Carcinoma (RCC)

RCC ECHO® MasterCourse – Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival

Brian I. Rini, MD, FASCO
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

April
15
Thursday
7:00 PM EDT

Multiple Sclerosis

The Rise of B-Cell Therapies in Relapsing MS: Examining the State of the Science, New Therapeutic Options, and Patient-Centered Clinical Decision-Making

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Ludwig Kappos, MD, FEAN, FAAN
Research Center Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
University Hospital Basel
University of Basel
Basel, Switzerland

April
17
Saturday
12:00 PM CDT
April
21
Wednesday
7:00 PM EDT

Multiple Myeloma

Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Emory University School of Medicine
Winship Cancer Institute of Emory University
Atlanta, Georgia

April
20
Tuesday
12:00 PM EDT

Interstitial Lung Disease (ILD)

The Importance of Early Recognition of Interstitial Lung Diseases: Practical Strategies for the Radiologist

Brett Elicker, MD
University of California
San Francisco, California

April
20
Tuesday
5:00 PM EDT

Myelodysplastic Syndromes

Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

Sara M. Tinsley, PhD, APRN, AOCN
Moffitt Cancer Center
University of South Florida, College of Nursing
Tampa, Florida

April
21
Wednesday
8:00 AM CDT

Acute Lymphoblastic Leukemia (ALL)

Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds

Elizabeth A. Raetz, MD
KiDS of NYU Foundation Professor of Pediatric Medicine
Director, Division of Pediatric Hematology/Oncology
NYU Langone Health
New York, New York

Rachel Rau, MD
Assistant Professor
Department of Pediatrics, Section of Hematology-Oncology
Texas Children's Cancer and Hematology Center
Baylor College of Medicine
Houston, Texas

April
22
Thursday
9:00 AM EDT

Chronic Lymphocytic Leukemia (CLL)

Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
22
Thursday
7:00 PM EDT

Ovarian Cancer

Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital
US Oncology Research Network
Phoenix, Arizona

Angeles Alvarez Secord, MD, MHSc
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

April
27
Tuesday
9:00 AM EDT

Diffuse Large B-Cell Lymphoma (DLBCL)

Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy

Lesley Camille Ballance, MSN, FNP-BC
Sarah Cannon Center for Blood Cancers at Tennessee Oncology
Nashville, Tennessee

April
27
Tuesday
9:00 AM EDT

Renal Cell Carcinoma (RCC)

The New Therapeutic Era in Renal Cell Carcinoma: Oncology Nursing Essentials for Patient Care

Laura S. Wood, RN, MSN, OCN
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

Sumanta Kumar Pal, MD
City of Hope Comprehensive Cancer Center
Duarte, California

April
29
Thursday
4:30 PM EDT
May
4
Tuesday
7:00 PM EDT

Hyperlipidemia

Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD

Professor Kausik Ray
European Atherosclerosis Society
Imperial Centre for Cardiovascular Disease Prevention
Imperial College London
London, England, United Kingdom

May
7
Friday
11:00 AM EDT
May
25
Tuesday
7:00 PM EDT

Hyperkalemia

Recognizing and Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease: An Update for Hospitalists

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

May
10
Monday
7:00 PM EDT

Chronic Kidney Disease

HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

Rajiv Agarwal, MD, MS
Indiana University School of Medicine
Indianapolis, Indiana

May
11
Tuesday
7:00 PM EDT

Esophageal/GEJ Cancer

Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer: The Latest Evidence and Implications for Thoracic Surgeons and the Multidisciplinary Care Team

Ronan J. Kelly, MD, MBA
Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas
Chief of Oncology, Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Chair of Immunology at Baylor University Medical Center
Clinical Professor, Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Professor, Clinical Sciences Division at the Translational Genomics Research Institute
Phoenix, Arizona

May
12
Wednesday
7:00 PM EDT

Atopic Dermatitis

Advancing Care for People Living With Moderate to Severe Atopic Dermatitis: The Future Looks Clear

Jonathan I. Silverberg, MD, PhD, MPH
George Washington University
School of Medicine and Health Sciences
Washington, DC

Eric Simpson, MD, MCR
Oregon Health & Science University
Portland, Oregon

May
13
Thursday
7:00 PM EDT

Lung Cancer

Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer

Brendon M. Stiles, MD
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

May
19
Wednesday
12:00 PM EDT

Chronic Fibrosing Interstitial Lung Disease (CF-ILD)

An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy

Kevin R. Flaherty, MD, MS
University of Michigan
Ann Arbor, Michigan

June
4
Friday
7:00 PM EDT

Basal Cell Carcinoma

Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
9
Wednesday
6:30 PM EDT

Chronic Lymphocytic Leukemia (CLL)

New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
10
Thursday
7:00 PM EDT

Renal Cell Carcinoma (RCC)

Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
10
Thursday
7:00 PM EDT

Breast cancer

Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

June
14
Monday
6:30 PM EDT

Chronic Lymphocytic Leukemia

Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care

Matthew S. Davids, MD, MMSc
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

June
14
Monday
7:00 PM EDT

HER2-Positive Breast Cancer

Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity

Sara Hurvitz, MD
Jonsson Comprehensive Cancer Center, UCLA
University of California, Los Angeles
Los Angeles, California

June
15
Tuesday
7:00 PM EDT

Melanoma

Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease

Jason J. Luke, MD, FACP
University of Pittsburgh Medical Center and Hillman Cancer Center
Pittsburgh, Pennsylvania

Geoffrey T. Gibney, MD
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, DC

June
15
Tuesday
7:00 PM EDT

Acute Myeloid Leukemia (AML)

Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
15
Tuesday
7:00 PM EDT

SCLC

Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
15
Tuesday
8:25 AM EDT
June
23
Wednesday
7:00 PM EDT

NF1

Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Nicole J. Ullrich, MD, PhD, MMSci
Boston Children’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
16
Wednesday
7:00 PM EDT

NSCLC

Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

June
16
Wednesday
7:00 PM EDT

Ovarian Cancer

The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice

Deborah K Armstrong, MD
The Skip Viragh Outpatient Cancer Center
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

June
17
Thursday
12:00 PM EDT

Acute Lymphoblastic Leukemia (ALL)

Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients

Nicola Gökbuget, MD
University Hospital
Frankfurt, Germany

June
17
Thursday
7:00 PM EDT

Breast Cancer

Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents

Sara M. Tolaney, MD, MPH
Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
17
Thursday
7:00 PM EDT

Obesity

Going With Your Gut: Targeting Long-Term Weight Loss With Current and Emerging Incretin-Based Pharmacotherapy

Christopher D. Still, DO, FACP, FTOS
Geisinger Commonwealth School of Medicine
Center for Nutrition & Weight Management
Geisinger Obesity Institute
Geisinger Health System
Danville, Pennsylvania

Alan C. Wittgrove, MD, FASMBS, FACS
Wittgrove Bariatric Center
Del Mar, California

June
17
Thursday
7:00 PM EDT

Multiple Myeloma

Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
22
Tuesday
7:00 PM EDT

Gastrointestinal Cancers

Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers

Jaffer A. Ajani, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ian Chau, MD, FRCP
The Royal Marsden Hospital
London and Surrey, United Kingdom

June
23
Wednesday
7:00 PM EDT
July
8
Thursday
7:00 PM EDT

GLP-1 RAs

The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

James R. Gavin III, MD, PhD
Healing Our Village, Inc.
Emory University School of Medicine
Atlanta, Georgia

July
22
Thursday
7:00 PM EDT

Gastric and GEJ Cancer

Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

Manish A. Shah, MD, FASCO
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Weill Cornell Medicine/New York-Presbyterian Hospital
New York, New York

August
3
Tuesday
7:00 PM EDT

Venous Thromboembolism (VTE)

Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes

Alok A. Khorana, MD, FACP, FASCO
Taussig Cancer Institute
Cleveland Clinic Lerner School of Medicine
Case Western Reserve University
Cleveland, Ohio

Robert D. McBane, II, MD
Mayo Clinic Gonda Vascular Center
Rochester, Minnesota

August
19
Thursday
7:00 PM EDT

B-Cell Cancers

The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

August
26
Thursday
7:00 PM EDT

Psoriasis

Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

April W. Armstrong, MD, MPH
Southern California Clinical and Translational Science Institute (SC CTSI)
Keck School of Medicine
University of Southern California
Los Angeles, California

Kenneth B. Gordon, MD
Medical College of Wisconsin
Milwaukee, Wisconsin

September
1
Wednesday
7:00 PM EDT
September
9
Thursday
6:15 AM CDT

Chronic Lymphocytic Leukemia

Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Jennifer Woyach, MD
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

September
10
Friday
6:30 AM CDT

Myelofibrosis

Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

September
14
Tuesday
5:00 PM EDT

Non–Small Cell Lung Cancer

Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Melissa L. Johnson, MD
Sarah Cannon Research Institute
Nashville, Tennessee

September
14
Tuesday
7:00 PM EDT

Multiple Myeloma

Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

September
28
Tuesday
5:00 PM CDT

Immuno-Oncology Biomarkers

Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy

Kurt A. Schalper, MD, PhD
Assistant Professor of Pathology and Medical Oncology
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

October
22
Friday
6:00 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:30 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
7:00 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

Christopher Baugh, MD, MBA
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
7:00 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
7:00 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:30 PM EDT
October
29
Friday
6:05 PM EDT

Small Cell Lung Cancer

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Jonathan W. Goldman, MD
UCLA Jonsson Comprehensive Cancer Center
Ronald Reagan UCLA Medical Center
UCLA Health - Santa Monica Medical Center
Santa Monica, California

November
2
Tuesday
7:00 PM EDT
November
8
Monday
7:00 PM EST
November
3
Wednesday
12:30 PM EDT

Atopic Dermatitis

Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis

Emma Guttman-Yassky, MD, PhD
Icahn School of Medicine
Mount Sinai Medical Center
New York, New York

November
3
Wednesday
7:00 PM EDT
November
15
Monday
7:00 PM EST

Esophageal/GEJ Cancer

Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care

Ronan J. Kelly, MD, MBA
Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas
Chief of Oncology, Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Chair of Immunology at Baylor University Medical Center
Clinical Professor, Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Professor, Clinical Sciences Division at the Translational Genomics Research Institute
Phoenix, Arizona

Daniela Molena, MD
Director, Esophageal Surgery Program
Memorial Sloan Kettering Cancer Center
New York, New York

November
4
Thursday
9:00 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
4
Thursday
7:00 PM EDT
November
22
Monday
7:00 PM EST

NSCLC

Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease

Stephen R. Broderick, MD, MPHS
Johns Hopkins University School of Medicine
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Heather A. Wakelee, MD
Stanford Cancer Center
Stanford, California

November
7
Sunday
5:30 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
8
Monday
7:00 PM EST
November
15
Monday
7:00 PM EST

Breast Cancer

Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

November
9
Tuesday
7:00 PM EST

Obesity

Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

Domenica M. Rubino, MD
Washington Center for Weight Management and Research
Arlington, Virginia

Donna H. Ryan, MD, FTOS
Pennington Biomedical Research Center
Baton Rouge, Louisiana

November
10
Wednesday
7:00 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
13
Saturday
6:30 AM EST

Hypertrophic Cardiomyopathy

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

November
14
Sunday
8:30 AM EST
November
17
Wednesday
7:00 PM EST

HCC/Liver Cancer

Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas

November
14
Sunday
5:00 PM EST

Cardiac irAEs

Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?

Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California

November
16
Tuesday
7:00 PM EST

HIV

Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient

David Malebranche, MD, MPH
Internal Medicine Physician
Atlanta, Georgia

Peter Shalit, MD, PhD
University of Washington
Seattle, Washington

November
20
Saturday
12:45 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:45 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
7:00 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
7
Thursday
8:00 AM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

December
10
Friday
7:00 AM EST

Follicular Lymphoma

A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST

Chronic Lymphocytic Leukemia (CLL)

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:30 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:30 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:30 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST
December
17
Friday
6:30 PM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
14
Tuesday
10:00 AM EST

Eosinophilic Esophagitis

Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy

Chris A. Liacouras, MD
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

December
21
Tuesday
7:00 PM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

January
20
Thursday
6:30 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:15 PM PST
January
29
Saturday
1:30 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

January
30
Sunday
1:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
9
Wednesday
7:00 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
7:00 PM PST
February
17
Thursday
7:00 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:30 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
22
Tuesday
3:05 PM PST
March
8
Tuesday
6:30 PM EST

NSCLC

Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

Pasi A. Jänne, MD, PhD
Lowe Center for Thoracic Oncology
Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

February
23
Wednesday
7:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
24
Thursday
7:00 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
25
Friday
7:00 PM EST
March
7
Monday
7:00 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
7:00 AM MST

Severe Asthma

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
7:15 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
5:15 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
21
Monday
3:00 PM MST

Ovarian Cancer

When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum

Bradley J. Monk, MD, FACS, FACOG
University of Arizona College of Medicine
Creighton University School of Medicine
GOG-Foundation
Phoenix, Arizona

March
22
Tuesday
6:15 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:15 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
31
Thursday
7:00 PM EDT

Cancer Screening

Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

Elizabeth Eaman, MD
Oodle Family Medicine
Renton, Washington
Healthy Transitions, LLC
Montclair, New Jersey
University of Washington
Seattle, Washington

April
7
Thursday
7:00 PM EDT

T2DM and Obesity

Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

Javier Morales, MD, FACP, FACE
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Advanced Internal Medicine Group, PC
East Hills, New York

April
9
Saturday
7:00 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
12
Tuesday
6:00 PM CDT

Ovarian Cancer

Making Sense of The Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy

Thomasina Morris, RPh, MHA, BCOP
Moffitt Cancer Center
Tampa, Florida

April
19
Tuesday
7:00 PM EDT
April
26
Tuesday
7:00 PM EDT
April
28
Thursday
12:15 PM PDT
April
29
Friday
6:00 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
6:00 PM PDT
May
5
Thursday
7:30 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:45 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
12:30 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
14
Saturday
6:00 PM CDT
June
1
Wednesday
7:30 PM EDT

Asthma

The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

Reynold A. Panettieri, Jr., MD
Robert Wood Johnson Medical School
Rutgers Institute for Translational Medicine and Science
Rutgers University
New Brunswick, New Jersey
University of Pennsylvania

Eileen Wang, MD, PhD
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

June
2
Thursday
7:00 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
7:00 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
7:00 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: mpact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
7:00 PM CDT
June
3
Friday
7:00 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
7:00 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
7:00 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
6:00 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
7:00 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
7:00 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
7:00 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
7:00 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
7:00 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
7:00 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
7:00 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
7:00 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
7:00 PM CDT
June
5
Sunday
7:00 PM CDT
June
15
Wednesday
12:00 PM EDT
July
1
Friday
13:40 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York

December
10
Friday
7:30 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
11:30 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

Live event schedule coming soon. Questions about upcoming live events can be sent to live@PeerView.com.
September
11
Wednesday
11:00 AM

Immuno-Oncology Biomarkers

A Pan-Cancer, Pan-Biomarker Exploration of the Opportunities to Realize the Potential of Precision Immuno-Oncology: Are Pathology Professionals Ready for the Challenge?

Phoenix, Arizona

Kurt Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

September
13
Friday
11:00 AM

Leukemia

Pathology Insights on Innovation in AML: The Rapid Emergence of Precision Diagnostics & Novel Therapy Across the Spectrum of Care

Phoenix, Arizona

Carlos E. Bueso-Ramos, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
16
Monday
5:45 PM

NSCLC

NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

Chicago, Illinois

Roy H. Decker, MD, PhD
Professor & Vice Chair
Director of Clinical Research
Department of Therapeutic Radiology
Yale School of Medicine
New Haven, Connecticut

September
16
Monday
5:45 PM

Solid Tumors

Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence, & Clinical Application Across a Range of Solid Malignancies

Chicago, Illinois

Matthew T. Ballo, MD, FACR
Professor and Chair of Radiation Oncology
West Cancer Center & Research Institute
Memphis, Tennessee

September
17
Tuesday
6:15 PM

EGFR-Mutant NSCLC

Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes

Chicago, Illinois

Kathryn Beal, MD
Radiation Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Sandip Patel, MD
Associate Professor, Department of Medicine
UC San Diego Health
Co-Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
Assistant Director, Clinical Trials Office
UC San Diego Moores Cancer Center
La Jolla, California

September
17
Tuesday
6:15 PM

EGFR-Mutant NSCLC

Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes

Chicago, Illinois

Kathryn Beal, MD
Radiation Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Sandip Patel, MD
Associate Professor, Department of Medicine
UC San Diego Health
Co-Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
Assistant Director, Clinical Trials Office
UC San Diego Moores Cancer Center
La Jolla, California

September
22
Sunday
6:30 AM

Renal Cell Carcinoma

The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

Lake Buena Vista, Florida

Julia Batten, APRN, MSN, MPH
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

September
23
Monday
5:15 PM

Precision Immuno-Oncology

A Pan-Cancer, Pan-Biomarker Exploration of the Opportunities to Realize the Potential of Precision Immuno-Oncology: Are Pathology Professionals Ready for the Challenge?

Kissimmee, Florida

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

September
25
Wednesday
11:00 AM

Asthma

Teaming Up to Overcome Challenges in Severe Asthma Management: The Role of Targeted Therapy in Personalized Care

Philadelphia, Pennsylvania

William J. Calhoun, MD, FACP, FCCP, FAAAAI, FACAAI
University of Texas Medical Branch
Galveston, Texas

Neil Skolnik, MD
Sidney Kimmel Medical College
Thomas Jefferson University
Abington Jefferson Health
Abington, Pennsylvania

October
22
Tuesday
5:30 AM

Chronic obstructive pulmonary disease (COPD)

Winning Strategies for Diagnosing and Managing Chronic Obstructive Pulmonary Disease

New Orleans, Louisiana

Fernando J. Martinez, MD, MS
Weill Cornell Medical College
New York-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

MeiLan K. Han, MD, MS
University of Michigan
Ann Arbor, Michigan

October
22
Tuesday
11:00 AM
October
26
Saturday
6:00 PM

Emergency Medicine

Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

Denver, Colorado

Evan J. Lipson, MD
Bloomberg~Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrew Stolbach, MD, MPH
Johns Hopkins Hospital
Johns Hopkins University School of Medicine
Baltimore, Maryland

October
29
Tuesday
6:00 AM

Hemophilia

Recognizing and Managing Hemophilia in the Emergency Department in an Era of Expanding Therapeutic Options: A Progress-in-Practice MasterClass and Practicum

Denver, Colorado

Sarah Luisa Melendez, MD
Orlando Health Arnold Palmer Hospital for Children
Orlando, Florida

Doris Quon, MD, PhD
Orthopaedic Hemophilia Treatment Center
Los Angeles, California

November
11
Monday
6:30 PM
November
13
Wednesday
12:30 PM

Rheumatology

Recognizing and Managing Progressive Fibrosing ILD in Patients With Connective Tissue Diseases: Examining the Potential Clinical Implications of Antifibrotic Therapy

Atlanta, Georgia

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

Kevin R. Flaherty, MD, MS
University of Michigan
Ann Arbor, Michigan

November
16
Saturday
10:33 AM

Renal Cell Carcinoma

How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

Miami, Florida

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

November
16
Saturday
18:30 PM

TGCT (Tenosynovial Giant Cell Tumor)

Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science

Tokyo, Japan

Robin L. Jones, MD
Royal Marsden Hospital and
Institute of Cancer Research
London, England, United Kingdom

November
17
Sunday
6:00 AM

Diabetes

Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

Philadelphia, PA

Mikhail Kosiborod, MD, FACC, FAHA
Saint Luke’s Health System
Haverty Cardiometabolic Center of Excellence
Cardiometabolic Research Program, Saint Luke’s Mid America Heart Institute
University of Missouri
Kansas City, Missouri

November
21
Thursday
5:30 PM

Glioblastoma

Brainstorming Personalized Care Strategies in Glioblastoma - Rethinking and Refining Therapeutic Algorithms With Tumor Treating Fields and Novel Systemic Approaches

Phoenix, AZ

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

December
6
Friday
7:00 AM

Lymphoma

'How I Think, How I Treat'
BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps

Orlando, Florida

Andre H. Goy, MD
John Theurer Cancer Center
Regional Cancer Care Associates
Georgetown University
Seton Hall
Hackensack Meridian School of Medicine
Hackensack, New Jersey

December
6
Friday
7:00 AM

Lymphoma

Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL

Orlando, Florida

John P. Leonard, MD
Weill Cornell Medicine
New York, New York

December
9
Monday
10:45 AM

Anemia in Chronic Kidney Disease

Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

Las Vegas, Nevada

Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana

January
23
Thursday
5:45 PM

HCC/Liver cancer

Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook

San Francisco, California

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
24
Friday
5:30 AM

Inflammatory bowel disorder (IBD)

Transforming the Management of Inflammatory Bowel Disease: A Closer Look at the Role of JAK Inhibitors and the Patient’s Perspective in Achieving Therapeutic Goals

Austin, TX

David T. Rubin, MD
Digestive Diseases Center
University of Chicago Medicine
Chicago, Illinois

January
24
Friday
5:30 PM

Biliary Cancers

Blazing the Therapeutic Management Trail of Biliary Cancers: Get Prepared for a New Era of Molecular- and Mutation-Driven Treatments

San Francisco, CA

Milind Javle, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas


February
13
Thursday
6:30 PM

Bladder cancer

Raising the Bar With Innovative Therapy for Bladder Cancer: Insights on Clinical Decision-Making in the New Era of Care

San Francisco, CA

Arjun Balar, MD
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

February
14
Friday
6:15 PM

Oncology

Mapping the Pathways to Better Patient Outcomes in Prostate Cancer: Personal Insights and Guidance from the Patient CaseBook

San Francisco, CA

William K. Oh, MD
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

February
19
Wednesday
12:00 PM

Veno-occlusive disease (VOD)

Following the Trail of Evidence in VOD Management: How Modern Risk Assessment, Diagnostic Principles, and Treatment Are Improving Care

Orlando, FL

Mitchell S. Cairo, MD
Children and Adolescent Cancer and Blood Diseases Center
Maria Fareri Children’s Hospital
Westchester Medical Center (WMC)
New York Medical College
Valhalla, New York

February
20
Thursday
6:30 AM

CAR T Cell Therapy

Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers

Orlando, Florida

Michael R. Bishop, MD
University of Chicago
Chicago, Illinois

February
20
Thursday
12:00 PM

Hematology-Oncology

Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

Orlando, Florida

Roy F. Chemaly, MD, MPH, FIDSA, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
21
Friday
12:00 PM

Hematology-Oncology

Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options

Orlando, Florida

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Philippe Moreau, MD
University Hospital of Nantes
Nantes, France

February
22
Saturday
12:00 PM

Acute Myeloid Leukemia

The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant

Orlando, FL

Harry P. Erba, MD, PhD
Duke University Medical Center
Durham, North Carolina

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Mayo Clinic
Jacksonville, Florida

February
27
Thursday
5:15 PM

Head and Neck Cancer

Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment Strategies

Scottsdale, AZ

Barbara Burtness, MD
Yale University School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
02
Monday
6:00 AM

HER2 Testing/Treatment

Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists

Los Angeles, California

Farnaz Dadmanesh, MD
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Laura H. Tang, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

March
3
Tuesday
6:00 AM

Leukemia

Precision Diagnostics and Modern Therapy in AML: Innovation and Insights for Pathologists on Personalized Medicine and Team-Based Care

Los Angeles, California

Carlos E. Bueso-Ramos, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

March
4
Wednesday
6:00 AM

Immuno-Oncology Biomarkers

Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

Los Angeles, California

Kurt Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
17
Tuesday
5:30 PM

ASMD

Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

San Antonio, TX

Robin Lachmann, MD, PhD
National Hospital for Neurology and Neurosurgery
University College London Hospitals
London, United Kingdom

March
20
Friday
6:45 AM

PARP

Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing

San Antonio, TX

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital
US Oncology Research Network
Phoenix, Arizona

Mike Janicek, MD
Medical Director
Virginia G. Piper Cancer Genetic Risk Assessment Center
Arizona Oncology Genetics Program
President
Arizona Oncology (US Oncology Network)
Phoenix Division
Scottsdale, Arizona

March
27
Friday
5:30 PM
March
27
Friday
5:30 PM

Breast Cancer

Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer

Boston, MA

Elizabeth A. Mittendorf, MD, PhD
Brigham and Women’s Hospital
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts

April
22
Wednesday
6:00 AM

SCLC

Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Implications for the “Four Ps” in Managed Care Settings—Patient, Provider, Pharmacy, and Plan

Houston, Texas

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

May
2
Saturday
5:30 PM

Leukemia

Meeting the Many Challenges of AML: Oncology Nurse Tactics for a Complex Disease in an Era of Novel Therapies

San Antonio, TX

Sara M. Tinsley, PhD, APRN, AOCN
University of South Florida, College of Nursing
Moffitt Cancer Center
Tampa, Florida

April
3
Wed
7:30 AM

Phenylketonuria

Diminishing the Burden of Phenylketonuria During Adulthood: New Science & Encouraging Stories Highlighting the Critical Role of Adjunctive Therapy in Alleviating Neurocognitive Symptoms and Easing Dietary Constraints

Seattle, WA

Jerry Vockley, MD, PhD
University of Pittsburgh
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania

Stephanie Sacharow, MD, FACMG
Harvard Medical School
Boston Children’s Hospital
Boston, Massachusetts

May
3
Friday
5:30 PM

Bladder Cancer

Advancing the Management of Urothelial Cancer With Immuno-Oncology and Targeted Approaches: Key Concepts for Urology Professionals on the Front Lines of Care

Chicago, Illinois

Neal D. Shore, MD, FACS
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

May
4
Saturday
6:15 AM

Breast Cancer

On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum

Dallas, TX

Elizabeth A. Mittendorf, MD, PhD
Brigham and Women’s Hospital
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts

May
5
Sunday
6:00 PM
May
19
Sunday
6:30 PM

Pulmonology

Systemic Sclerosis–Associated Interstitial Lung Disease: Expert Insights on Early Diagnosis and Optimal Management

Dallas, Texas

Marilyn K. Glassberg, MD
University of Miami School of Medicine
Miami, Florida

May
30
Thursday
6:30 AM

Multiple Sclerosis

Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers

Seattle, Washington

Edward J. Fox, MD, PhD
MS Clinic of Central Texas
Central Texas Neurology Consultants
University of Texas Dell Medical School
Round Rock, Texas

May
31
Friday
6:30 PM

Head and Neck Cancer

Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care

Chicago, Illinois

Ezra Cohen, MD, FRCPSC, FASCO
UC San Diego Health
San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

May
31
Friday
6:30 PM

Pancreatic Cancer

Stories From The Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes With Modern Therapeutic Concepts and Innovative Treatments

Chicago, Illinois

Johanna C. Bendell, MD
Sarah Cannon Research Institute
Nashville, Tennessee

May
31
Friday
6:30 PM

Renal Cell Carcinoma

Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy

Chicago, Illinois

David F. McDermott, MD
Beth Israel Deaconess Medical Center
Dana-Farber Harvard Cancer Center Kidney Cancer Program
Harvard Medical School
Boston, Massachusetts

May
31
Friday
6:30 PM

Lymphoma

A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care

Chicago, Illinois

Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

May
31
Friday
6:30 PM

Myelofibrosis

MasterClass and Case Forum: Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

Chicago, Illinois

Professor Claire Harrison
Guy's and St Thomas' NHS Foundation Trust
South London Genomics Medicine Centre
London, England, United Kingdom

June
1
Saturday
6:30 PM

Prostate Cancer

New Concepts in Prostate Cancer Care: What Oncologists Need to Know to Optimize Patient Outcomes

Chicago, Illinois

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

June
1
Saturday
6:30 PM

Hepatocellular Carcinoma

“How I Think, How I Treat”—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC

Chicago, Illinois

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
Weill Medical College at Cornell University
New York, New York

June
1
Saturday
6:30 PM

Non—Small Cell Lung Cancer

Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient

Chicago, Illinois

Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia

September
10
Friday
7:15 PM MDT

Hypertrophic Cardiomyopathy

Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

Aurora, Colorado

Daniel Jacoby, MD
Yale New Haven Health
Yale School of Medicine
New Haven, Connecticut

October
22
Friday
5:30 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Las Vegas, NV

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:00 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Chicago, IL

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
6:30 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Boston, MA

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
6:30 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Orlando, Florida

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
6:30 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Orlando, Florida

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:15 PM EDT

NSCLC

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Boston, MA

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

November
4
Thursday
8:30 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Austin, TX

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
20
Saturday
12:15 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Boston, MA

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:30 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Orlando, FL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
6:30 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Orlando, FL

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
10
Friday
7:00 AM EST

Chronic Lymphocytic Leukemia

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

Atlanta, GA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:00 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Atlanta, GA

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:00 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Atlanta, GA

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
7:00 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Atlanta, GA

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:00 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Atlanta, GA

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:00 AM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Atlanta, GA

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
10
Friday
11:00 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Atlanta, GA

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

January
20
Thursday
6:00 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

San Francisco, CA

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:00 PM PST

Biliary Cancers

Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

San Francisco, CA

Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
9
Wednesday
6:30 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

New Orleans, LA

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
6:45 PM PST

Renal Cell Carcinoma

Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies

San Francisco, CA

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

February
17
Thursday
6:45 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

San Francisco, CA

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:15 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

San Francisco, CA

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
25
Friday
6:30 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

West Palm Beach, FL

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
6:30 AM MST

Severe Asthma

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Phoenix, AZ

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
6:45 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Dallas, TX

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
4:45 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Dallas, TX

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
17
Thursday
5:00 PM CET

Alzheimer’s Disease

Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

Barcelona, Spain

Liana G. Apostolova, MS, MD, FAAN
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

March
22
Tuesday
6:00 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:00 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
26
Saturday
6:30 PM EDT

Prurigo Nodularis

Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

Boston, MA

Sarina Elmariah, MD, PhD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Shawn Kwatra, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

March
27
Sunday
6:30 PM EDT

Chronic Spontaneous Urticaria

Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

Boston, MA

Joseph Diaz, MD
Allergy, Asthma, & Immunology Associates of South Texas
San Antonio, Texas

Erika Gonzalez, MD
South Texas Allergy & Asthma Medical Professionals
University of Texas Health Science Center
San Antonio, Texas

April
9
Saturday
6:30 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

New Orleans

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
24
Sunday
12:00 PM MST

Graft-Versus-Host Disease

Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

Salt Lake City, UT

Leslie Kean, MD, PhD
Harvard Medical School
Boston Children's Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts

April
25
Monday
6:30 AM MDT

Acute Myeloid Leukemia

Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

Salt Lake City, UT

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida

April
25
Monday
7:00 AM MDT

Leukemia

CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma

Salt Lake City, UT

Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois

April
26
Tuesday
6:30 AM MDT

Myelofibrosis

The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Salt Lake City, UT

Jeanne M. Palmer, MD
Mayo Clinic
Phoenix, Arizona

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

April
26
Tuesday
6:30 AM MST

Chronic Lymphocytic Leukemia

Reaping the Rewards of Innovative Care in CLL: From Targeted Standards to Cellular Therapy

Salt Lake City, UT

John N. Allan, MD
Weill Cornell Medicine
New York, New York

Alexey V. Danilov, MD, PhD
Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

April
26
Tuesday
11:30 AM MDT

Veno-Occlusive Disease

Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment

Salt Lake City, UT

Nelson Chao, MD, MBA
Duke Cancer Institute/Duke Global Health Institute
Durham, North Carolina

Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts

April
28
Thursday
11:45 AM PDT

Solid Tumors

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

Anaheim, CA

Linda Ahn, MSN, ANP-BC, AOCNP
Memorial Sloan Kettering Cancer Center
New York, New York

April
29
Friday
5:30 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Anaheim, CA

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
5:30 PM PDT

Renal Cell Carcinoma

Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies

Anaheim, CA

Nancy P. Moldawer, RN, MSN
Cedars-Sinai Medical Center
Los Angeles, California

May
5
Thursday
7:00 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Pittsburgh, PA

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:15 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Pittsburgh, PA

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
5:30 PM CDT
May
14
Saturday
12:00 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Boston, MA

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

June
2
Thursday
6:30 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

National Harbor, MD

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
6:30 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Chicago, Illinois

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
6:30 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: mpact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

National Harbor, MD

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
6:30 PM CDT

Melanoma

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Chicago, Illinois

Hussein A. Tawbi, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

June
3
Friday
6:30 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Chicago, IL

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
6:30 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Chicago, IL

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
6:30 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Chicago, IL

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
5:30 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

New Orleans, Louisiana

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Boston, MA

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
6:30 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Chicago, IL

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
6:30 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Chicago, IL

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
6:30 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Chicago, IL

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
6:30 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Chicago, IL

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
6:30 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Chicago, IL

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
6:30 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

Chicago, IL

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
6:30 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Chicago, IL

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
6:30 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Chicago, IL

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
6:30 PM CDT

BLADDER CANCER

Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum

Chicago, IL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

June
5
Sunday
6:30 PM CDT

METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Chicago, IL

Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

June
9
Thursday
07:45 CEST

B-Cell Cancers

Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

Wien, Austria

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
9
Thursday
10:00 CEST

Chronic Lymphocytic Leukemia

New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management

Wien, Austria

Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany

June
10
Friday
17:45 CEST

ACUTE LYMPHOBLASTIC LEUKEMIA

The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients

Wien, Austria

Prof. Carmelo Rizzari
President of the European Society of Pediatric Oncology (SIOPE)
Professor of Pediatrics
University of Milano-Bicocca
Head, Pediatric Hematology Oncology Unit
MBBM Foundation, ASST Monza
Monza, Italy

June
15
Wednesday
11:45 AM EDT
July
1
Friday
13:25 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Barcelona, Spain

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York